November 02, 2013
1 min read

CAP outcomes equal with broad-, narrow-spectrum therapy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Different clinical outcomes and costs are not seen in children hospitalized with community-acquired pneumonia whether they are treated with narrow- or broad-spectrum antimicrobial therapy, according to recent study findings published in Pediatrics.

The study included 15,564 children aged 6 months to 18 years hospitalized with community-acquired pneumonia (CAP) between July 1, 2005, and June 30, 2011, who received either parenteral ampicillin/penicillin (narrow spectrum) or ceftriaxone/cefotaxime (broad spectrum) treatment.

Overall, 89.7% of participants received broad-spectrum therapy and 10.3% received narrow-spectrum. Median length of stay was 3 days for both groups (adjusted difference, 0.12 days; 95% CI, –0.02 to 0.26).

One percent of patients receiving broad-spectrum therapy and 0.8% receiving narrow-spectrum therapy were admitted to the ICU (adjusted OR=0.85; 95% CI, 0.27-2.73). Readmission occurred in 2.3% of patients receiving broad-spectrum and 2.4% of patients receiving narrow-spectrum therapy. Hospitalization median costs were $3,992 for broad-spectrum therapy and $4,375 for narrow-spectrum therapy.

“Clinical outcomes and costs for children hospitalized with CAP are not different when empirical treatment is with narrow-spectrum compared with broad-spectrum therapy,” the researchers wrote. “Few institutions used narrow-spectrum therapy routinely before publication of the PIDS/IDSA CAP management guidelines. Programs promoting guideline implementation and targeting judicious antibiotic selections for CAP are needed to optimize management of childhood CAP in the United States.”

Disclosure: The researchers report no relevant financial disclosures.